Stock Track | Relay Therapeutics Plummets 6.15% Intraday Following Q1 Earnings Miss and Revenue Decline

Stock Track05-06

Relay Therapeutics' stock plummeted 6.15% during intraday trading on Wednesday, extending losses from the previous session's post-market decline.

The sharp drop appears to be a continuation of negative investor sentiment following the company's first-quarter 2026 financial results. Relay Therapeutics reported a quarterly loss of $0.41 per diluted share, which narrowed from $0.46 a year earlier but missed the analyst consensus estimate of a $0.37 loss. Revenue for the quarter was $3 million, representing a significant 60.9% decline from the $7.7 million reported in the same period last year.

Despite receiving a Buy rating and $18 price target from Oppenheimer analyst Matthew Biegler earlier in the session, investors focused on the earnings miss and substantial year-over-year revenue drop, driving the stock lower throughout the trading day.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182386785?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182386785","market":"nz","top_or_hot":-1,"title":"Stock Track | Relay Therapeutics Plummets 6.15% Intraday Following Q1 Earnings Miss and Revenue Decline","media":"Stock Track","content":"<p>Relay Therapeutics' stock plummeted 6.15% during intraday trading on Wednesday, extending losses from the previous session's post-market decline.</p><p>The sharp drop appears to be a continuation of negative investor sentiment following the company's first-quarter 2026 financial results. Relay Therapeutics reported a quarterly loss of $0.41 per diluted share, which narrowed from $0.46 a year earlier but missed the analyst consensus estimate of a $0.37 loss. Revenue for the quarter was $3 million, representing a significant 60.9% decline from the $7.7 million reported in the same period last year.</p><p>Despite receiving a Buy rating and $18 price target from Oppenheimer analyst Matthew Biegler earlier in the session, investors focused on the earnings miss and substantial year-over-year revenue drop, driving the stock lower throughout the trading day.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Relay Therapeutics Plummets 6.15% Intraday Following Q1 Earnings Miss and Revenue Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Relay Therapeutics Plummets 6.15% Intraday Following Q1 Earnings Miss and Revenue Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Relay Therapeutics' stock plummeted 6.15% during intraday trading on Wednesday, extending losses from the previous session's post-market decline.</p><p>The sharp drop appears to be a continuation of negative investor sentiment following the company's first-quarter 2026 financial results. Relay Therapeutics reported a quarterly loss of $0.41 per diluted share, which narrowed from $0.46 a year earlier but missed the analyst consensus estimate of a $0.37 loss. Revenue for the quarter was $3 million, representing a significant 60.9% decline from the $7.7 million reported in the same period last year.</p><p>Despite receiving a Buy rating and $18 price target from Oppenheimer analyst Matthew Biegler earlier in the session, investors focused on the earnings miss and substantial year-over-year revenue drop, driving the stock lower throughout the trading day.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLAY","symbol_name":"Relay Therapeutics","start_time":0,"source_url":"","article_id":"1182386785","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182386785","pubTimestamp":1778078295,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Relay Therapeutics' stock plummeted 6.15% during intraday trading on Wednesday, extending losses from the previous session's post-market decline.The sharp drop appears to be a continuation of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLAY":"Relay Therapeutics"},"translate_title":"个股追踪|Q1财报不及营收下滑Relay Therapeutics盘中暴跌6.15%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLAY":1},"content_text":"Relay Therapeutics' stock plummeted 6.15% during intraday trading on Wednesday, extending losses from the previous session's post-market decline.The sharp drop appears to be a continuation of negative investor sentiment following the company's first-quarter 2026 financial results. Relay Therapeutics reported a quarterly loss of $0.41 per diluted share, which narrowed from $0.46 a year earlier but missed the analyst consensus estimate of a $0.37 loss. Revenue for the quarter was $3 million, representing a significant 60.9% decline from the $7.7 million reported in the same period last year.Despite receiving a Buy rating and $18 price target from Oppenheimer analyst Matthew Biegler earlier in the session, investors focused on the earnings miss and substantial year-over-year revenue drop, driving the stock lower throughout the trading day.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182386785","isCrawlerRequest":true}